Jakarta, 2022 — initial formulation review, revision 01-A
Saltora was formed from an observation rather than an ambition. The Indonesian men's supplement market — already substantial and growing — had standardised on a particular kind of product: high-ingredient-count labels, unverified quantities, and sourcing documentation that did not exist beyond the label itself. The gap between what was claimed and what was traceable was, in most cases, total.
The Saltora formulations began not with a product concept but with a documentation standard. Before the first capsule was produced, a sourcing framework was established: every active ingredient would arrive with a certificate of composition from the originating supplier. Every production batch would be verified by an independent laboratory before entering the dispatch inventory. The lot record would be maintained for a minimum of five years from production date.
Only after that framework was in place did the composition work begin. The process of identifying which micronutrients to include in a men's daily complex drew on published nutritional research rather than market preference. Zinc — because it supports normal cognitive function and immune health. Magnesium — because it contributes to normal energy metabolism and reduces tiredness. Vitamin D3 — because it supports normal function of the immune system. Each inclusion required a documented role, not simply a market expectation.
The Jakarta facility opened its production line in late 2022. By mid-2023, the first three formulations had completed their independent batch verification and entered the product range. The archive now covers twelve production batches across those three compositions. The documentation framework has not changed since its first revision.
View full methodology
